



41

1646

Docket No. CEN-248

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David M. Knight, et al.

Serial No. : 09/920,262

Art Unit: 1646

Filed : August 1, 2001  
MARIA

Examiner: MERTZ, PREMA

For : ANTI-IL-12 ANTIBODIES, COMPOSITIONS, METHODS AND  
USES

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, Washington, D.C. 20231 on

10/29/03

(Date of Deposit)

Guy Kevin Townsend

(Name of applicant, assignee, or Registered Representative)

*Guy K. Townsend*

(Signature)

10/29/03

(Date of Signature)

RECEIVED

NOV 05 2003

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37  
C.F.R. §§1.97-1.98, information relating to the above-identified  
application is hereby disclosed. Inclusion of information in  
this statement is not to be construed as an admission that this  
information is material as that term is defined in 37 C.F.R.  
§1.56(b).

Applicant(s) reserve(s) the right to establish the  
patentability of the claimed invention over any of the  
information provided herewith, and/or to prove that this  
information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ There are no listed references which are not in the English language.


☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.


☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN-248/GKT. This form is submitted in triplicate.

Respectfully submitted,

  
\_\_\_\_\_  
Guy Kevin Townsend  
Reg. No. 34,033  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2517  
DATED: 10/29/03



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	09/920,262
Filing Date	August 1, 2001
First Named Inventor	David M. Knight
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN-248-NP

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
	B1	6,300,478	B1	Trinchieri et. l	October 09, 2001	
	B-2	5,891,680		Lieschke et. al	April 06, 1999	
	B3	5,811,523		Trinchieri et. al	Sept. 22, 1998	
	B4	5,648,467		Trinchieri et. al	July 15, 1997	
	B5	5,457,038		Trinchieri et. al	October 10, 1995	
	B-6	5,648,467		Trinchieri et. al	July 15, 1997	
	B-7	6,225,117	B1	Gately et. al	May 1, 2001	
	B8	5,780,597		Gately et. al	July 14, 1998	
	B-9	6,225,117	B1	Gately et. al	May 01, 2001	
	B10	5,891,680		Lieschke at. al	April 06, 1999	
	B11	6,338,848	B1	Leonard et. al	January 15, 2002	
	B12	6,495,667	B1	Bazan	Dec. 17, 2002	
	B13	5,547,852		Seller et. al	August 20, 1996	
	B14	6,086,876		Karp et. al	July 11, 2000	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
	B-15	WO	01/19373	A2	BASF AG.	03/22/2001		
	B16	WO	92/05256	A1	GENETICS INSTITUTE, INC.	04/02/1992		
	B17	WO	90/05147	A1	GENETICS INSTITUTE, INC.	05/17/1990		
	B18	WO	99/37682	A2	F. HOFFMANN- LA ROCHE AG	04/29/1999		
	B19	WO	00/56772	A1	BASF AG	09/28/2000		
	B20	EP	804581	B1	CORIXA CORP.	09/20/2001		
	B21	EP	433827	B1	F. HOFFMANN LA ROCHE AG	03/04/1998		
	B22	EP	790255	A2	F. HOFFMANN LA ROCHE AG	08/20/1997		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OCT 3 1 2003

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(use as many sheets as necessary)**

Sheet 2 of 2

<i>Application Number</i>	09/920,262
<i>Filing Date</i>	August 1, 2001
<i>First Named Inventor</i>	David M. Knight
<i>Group Art Unit</i>	
<i>Examiner Name</i>	
<i>Attorney Docket Number</i>	CEN-248-NP

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			T <sup>2</sup>
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
	B-23	A. U. GUBLER et. al (COEXPRESSION OF TWO DISTINCT GENES IS REQUIRED TO GENERATE SECRETED BIOACTIVE CYTOTOXIC LYMPHOCYTE MATURATION FACTOR) Proc. Natl. acad. Sci. USA. Vol. 88. pp 4143-4147- (May 1991) Immunology.	
	B-24	A. U. GUBLER et. al (CLONIC AND EXPRESSION OF CYTOTOXIC LYMPHOCYTE MATURATION FACTOR (CLMF) A HETERODIMERIC LYMPHOKINE THAT POTENTIATES NR. LAK NA D T-CELL REPONSES) Abstracts Journal of cellular Biochemistry Supplement 15 F: 70 (1991)	
	B-25	ALVIN S. STERN et al - (PURIFICATION TO HOMOGENEITY AND PARTIAL CHARACTERIZATION OF CYTOTOXIC LYMPHOCYTE MATURATION FACTOR FROM HUMAN B-LYMPHOBLASTOID CELLS) (JUNE 11, 1990) F. HOFFMANN LA ROCHE INC. NUTLEY NJ USA. Proc. National Acad. Sci. USA (Vol. 87, pp 6808-6812- Sept 1990- Immunology)	
	B-26	M. GATELY et. al. (REGULATION OF HUMAN LYMPHOCYTE PROLIFERATION BY A HETERODIMERIC CYTOKINE IL-12 (CYTOTOXIC LYMPHOCYTE MATURATION FACTOR) Vol.147- 874-882 No. 3. (August 1, 1991).(The Journal of Immunology)	
	B-27	R. CHIZZONITE et. al. (IL-12 MONOCLONAL ANTIBODIES SPECIFIC FOR THE 40-KdA SUBUNIT BLOCK RECEPTOR BINDING AND BIOLOGIC ACTIVITY ON ACTIVATED HUMAN LYMPHOBLASTS.) Vol. 147,1548-1556- No. 5 (Sept,1991) The Journal of Immunology.	
	B-28	SUSAN H. CHAN et. al. (INTRODUCTION OF INTERFERON PRODUCTION BY NATURAL KILLER CELL STIMULATORY FACTOR CHARACTERIZATION OF THE RESPONDER CELLS AND SYNERGY WITH OTHER INDUCERS) (THE ROCKEFELLER UNIVERSITY PRESS)- 0022-1007/91/04/0869/-Vol. 173 April 1991-pp869-879	
	B-29	ANNALISA D'ANDREA et. al. (PRODUCTION OF NATURAL KILLER CELL STIMULATORY FACTOR (INTERLEUKIN 12) BY PERIPHERAL BLOOD MONONUCLEAR CELL) J. Exp. Med. The Rockefeller university press- 0022-1007/92/11/1387 Vol. 176 November 1992. - pp: 1387-1398	
	B-30	MARKUS F. NEURATH et. al. (ANTIBODIES TO INTERLEUKIN 12 ABROGATE ESTABLISHED EXPERIMENTAL COLITIS IN MICE) The Journal of Experimental Medicine - Vol. 182- Nov. 1995- pp.1281-1290	
	B-31	R.W. CARTER. et. al. (PRODUCTION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES TO HUMAN INTERLEUKIN -12) HYBRIDOMA 16: 363-369 (1997)	
	B-32	NICOLAS M. VALIANTE et. al. ( ROLE OF THE PRODUCTION OF NATURAL KILLER CELL STIMULATORY FACTOR (NKSF/IL-12) IN THE ABILITY OF B CELL LINES TO STIMULATE T AND NK CELL PROLIFERATION). Cellular Immunology 145, 187-198-(1992)	
	B-33	RAINER DUCHMANN et. al. ( TOLERANCE TOWARDS RESIDENT INTESTINAL FLORA IN MICE IS ABROGATED IN EXPERIMENTAL COLITIS AND RESTORES BY TREATMENT WITH INTELUKIN-1 OR ANTIBODIES TO INTERLEUKIN-12) Eur. J. Immunol 196-26: 394-938	
	B-34	MICHIO KOBAYASHI et. al. I ( IDENTIFICATION AND PURIFICATION OF NATURAL KILLER CELL STIMULATORY FACTOR (NKSF) A CYTOKINE WITH MULTIPLE BIOLOGIC EFFECTS ON HUMAN LYMPHOCYTES) J. Exp. Med. The Rockefeller university Press- Vol. 170-(Sept. 1989) pp. 827-845	
	B-35	SYLVIE TREMBLEAU et. al. (THE ROLE OF IL-12 IN THE INDUCTION OF ORGAN-SPECIFIC AUTOIMMUNE DISEASES)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.